Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT

Toni Terry, Kalyani Raravikar, Nalurporn Chokrungvaranon, Peter D. Reaven

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Diabetes is increasing rapidly worldwide and frequently results in severe vascular complications. A target glycated hemoglobin of less than 7% has commonly been recommended in hopes of preventing both macrovascular and microvascular complications. Although results from trials of intensive glycemic control have generally supported the notion that lower glycated hemoglobin values reduce microvascular disease, the evidence for similar benefits for macrovascular disease has been less clear. As macrovascular disease is the major cause of morbidity and mortality in type 2 diabetes, this remains one of the more important unresolved clinical questions. Recent results from the ACCORD, ADVANCE, and VADT studies have challenged the conventional believe that lower glycated hemoglobin values should be pursued in all diabetic patients. Factors that may influence whether intensive glucose management is advisable include duration of diabetes, pre-existing macrovascular disease, hypoglycemic unawareness, and significant comorbidities. Glycated hemoglobin goals should account for these factors and be individualized for each patient.

Original languageEnglish (US)
Pages (from-to)79-88
Number of pages10
JournalCurrent Cardiology Reports
Volume14
Issue number1
DOIs
StatePublished - Feb 1 2012
Externally publishedYes

Fingerprint

Glycosylated Hemoglobin A
Type 2 Diabetes Mellitus
Preexisting Condition Coverage
Hypoglycemic Agents
Blood Vessels
Comorbidity
Morbidity
Glucose
Mortality

Keywords

  • ACCORD
  • ADVANCE
  • Advanced glycation end products
  • Atherosclerosis
  • Coronary artery calcium
  • Diabetes duration
  • Glycated hemoglobin
  • Hypoglycemic unawareness
  • Intensive glycemic control
  • Macrovascular disease
  • Metabolic memory
  • Microvascular disease
  • Type 2 diabetes
  • UGDP
  • UKPDS
  • VADT

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT. / Terry, Toni; Raravikar, Kalyani; Chokrungvaranon, Nalurporn; Reaven, Peter D.

In: Current Cardiology Reports, Vol. 14, No. 1, 01.02.2012, p. 79-88.

Research output: Contribution to journalArticle

@article{e34435b8ecfc403e9baf1725039da402,
title = "Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes?: Insights from ACCORD, ADVANCE, and VADT",
abstract = "Diabetes is increasing rapidly worldwide and frequently results in severe vascular complications. A target glycated hemoglobin of less than 7{\%} has commonly been recommended in hopes of preventing both macrovascular and microvascular complications. Although results from trials of intensive glycemic control have generally supported the notion that lower glycated hemoglobin values reduce microvascular disease, the evidence for similar benefits for macrovascular disease has been less clear. As macrovascular disease is the major cause of morbidity and mortality in type 2 diabetes, this remains one of the more important unresolved clinical questions. Recent results from the ACCORD, ADVANCE, and VADT studies have challenged the conventional believe that lower glycated hemoglobin values should be pursued in all diabetic patients. Factors that may influence whether intensive glucose management is advisable include duration of diabetes, pre-existing macrovascular disease, hypoglycemic unawareness, and significant comorbidities. Glycated hemoglobin goals should account for these factors and be individualized for each patient.",
keywords = "ACCORD, ADVANCE, Advanced glycation end products, Atherosclerosis, Coronary artery calcium, Diabetes duration, Glycated hemoglobin, Hypoglycemic unawareness, Intensive glycemic control, Macrovascular disease, Metabolic memory, Microvascular disease, Type 2 diabetes, UGDP, UKPDS, VADT",
author = "Toni Terry and Kalyani Raravikar and Nalurporn Chokrungvaranon and Reaven, {Peter D.}",
year = "2012",
month = "2",
day = "1",
doi = "10.1007/s11886-011-0238-6",
language = "English (US)",
volume = "14",
pages = "79--88",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes?

T2 - Insights from ACCORD, ADVANCE, and VADT

AU - Terry, Toni

AU - Raravikar, Kalyani

AU - Chokrungvaranon, Nalurporn

AU - Reaven, Peter D.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Diabetes is increasing rapidly worldwide and frequently results in severe vascular complications. A target glycated hemoglobin of less than 7% has commonly been recommended in hopes of preventing both macrovascular and microvascular complications. Although results from trials of intensive glycemic control have generally supported the notion that lower glycated hemoglobin values reduce microvascular disease, the evidence for similar benefits for macrovascular disease has been less clear. As macrovascular disease is the major cause of morbidity and mortality in type 2 diabetes, this remains one of the more important unresolved clinical questions. Recent results from the ACCORD, ADVANCE, and VADT studies have challenged the conventional believe that lower glycated hemoglobin values should be pursued in all diabetic patients. Factors that may influence whether intensive glucose management is advisable include duration of diabetes, pre-existing macrovascular disease, hypoglycemic unawareness, and significant comorbidities. Glycated hemoglobin goals should account for these factors and be individualized for each patient.

AB - Diabetes is increasing rapidly worldwide and frequently results in severe vascular complications. A target glycated hemoglobin of less than 7% has commonly been recommended in hopes of preventing both macrovascular and microvascular complications. Although results from trials of intensive glycemic control have generally supported the notion that lower glycated hemoglobin values reduce microvascular disease, the evidence for similar benefits for macrovascular disease has been less clear. As macrovascular disease is the major cause of morbidity and mortality in type 2 diabetes, this remains one of the more important unresolved clinical questions. Recent results from the ACCORD, ADVANCE, and VADT studies have challenged the conventional believe that lower glycated hemoglobin values should be pursued in all diabetic patients. Factors that may influence whether intensive glucose management is advisable include duration of diabetes, pre-existing macrovascular disease, hypoglycemic unawareness, and significant comorbidities. Glycated hemoglobin goals should account for these factors and be individualized for each patient.

KW - ACCORD

KW - ADVANCE

KW - Advanced glycation end products

KW - Atherosclerosis

KW - Coronary artery calcium

KW - Diabetes duration

KW - Glycated hemoglobin

KW - Hypoglycemic unawareness

KW - Intensive glycemic control

KW - Macrovascular disease

KW - Metabolic memory

KW - Microvascular disease

KW - Type 2 diabetes

KW - UGDP

KW - UKPDS

KW - VADT

UR - http://www.scopus.com/inward/record.url?scp=84857631399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857631399&partnerID=8YFLogxK

U2 - 10.1007/s11886-011-0238-6

DO - 10.1007/s11886-011-0238-6

M3 - Article

C2 - 22160862

AN - SCOPUS:84857631399

VL - 14

SP - 79

EP - 88

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 1

ER -